Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
circulating immune and cancer driver gene biomarkers precede prostate cancer diagnosis by over 10 yr
Original title: “Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.”
balanced double aortic arch with late onset symptoms detected on 18f fdg pet ct in an octogenarian with advanced prostate cancer a case report
Original title: “Balanced double aortic arch with late-onset symptoms detected on 18F-FDG PET/CT in an octogenarian with advanced prostate cancer: A case report.”
pygo2 ablation promotes lymphoid organization and sting dependent antitumor immunity in prostate cancer
Original title: “PYGO2 Ablation Promotes Lymphoid Organization and STING-Dependent Antitumor Immunity in Prostate Cancer.”
early functional and oncological outcomes after robot assisted radical prostatectomy in d amico high risk prostate cancer a prospective cohort study
Original title: “Early functional and oncological outcomes after robot-assisted radical prostatectomy in D'Amico high-risk prostate cancer: a prospective cohort study.”
ras raf mapk alterations in prostatic adenocarcinoma a multi institutional study
Original title: “RAS/RAF/MAPK Alterations in Prostatic Adenocarcinoma: A Multi-Institutional Study.”
Radiopharm Theranostics is a clinical ... and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety ... Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 180mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positi Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors · Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution As we execute on our clinical development strategy, we remain focused on unlocking the full potential of RAD202 and generating meaningful data that could support a differentiated radiotherapeutic option for HER2-positive patients in need of new treatment alternatives.”
Original title: “Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - BioSpace”
stereotactic radiotherapy for rib metastases from prostate cancer a multicenter real world analysis of local control pain response and treatment tolerance ribrisk
Original title: “Stereotactic radiotherapy for rib metastases from prostate cancer: A multicenter real-world analysis of local control, pain response, and treatment tolerance (RIBRISK).”
subclonal complete loss of cdkn1b as a common genomic alteration in prostate cancer associations with race and prostate cancer outcomes
Original title: “Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.”
penile metastasis from castration resistant prostate cancer a case report
Original title: “Penile Metastasis From Castration-Resistant Prostate Cancer: A Case Report.”
urethral metastasis of therapy induced neuroendocrine prostate cancer successfully managed with chemoradiotherapy a case report
Original title: “Urethral Metastasis of Therapy-Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report.”
pleomorphic giant cell carcinoma of the prostate treated with lutetium 177 psma
Original title: “Pleomorphic Giant Cell Carcinoma of the Prostate Treated With Lutetium-177 PSMA.”
impact of central review and mri image quality on prostate cancer diagnosis and biopsy decision making in referred patients
Original title: “Impact of central review and MRI image quality on prostate cancer diagnosis and biopsy decision-making in referred patients.”
sarcomatoid carcinoma of the prostate with both chondrosarcomatous and osteosarcomatous differentiation following androgen deprivation therapy a case report and diagnostic considerations
Original title: “Sarcomatoid Carcinoma of the Prostate With Both Chondrosarcomatous and Osteosarcomatous Differentiation Following Androgen Deprivation Therapy: A Case Report and Diagnostic Considerations.”
early and late ctcae and patient reported outcomes following prostate radiotherapy in the requite cohort
Original title: “Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.”
physician and patient reported outcomes following contemporary image guided intensity modulated proton therapy for prostate cancer results from the prospective pro cube study
Original title: “Physician- and Patient-Reported Outcomes Following Contemporary Image Guided Intensity Modulated Proton Therapy for Prostate Cancer: Results From the Prospective PRO-Cube Study.”
Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.
Original title: “ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come”
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
Original title: “ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer”
Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.
Original title: “ASCO: A battle of bispecifics, Eli Lilly’s big win and more”
solitary testicular metastasis from ductal prostate cancer 5 years after radical prostatectomy a case report
Original title: “Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.”
interpretable 1 f psma pet ct mri model for optimizing prostate biopsy decisions
Original title: “An interpretable (1)⁸F-PSMA PET/CT-MRI model for optimizing prostate biopsy decisions.”